Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM
Key Highlights
- ➤Lexeo to host PKP2-ACM educational investor event October 21, 2026
- ➤Event will discuss clinically meaningful arrhythmia endpoints and outcome measures
- ➤Lexeo identifies LX2020 as its PKP2-ACM therapeutic candidate
Expert Statements
Narinder Bhalla, Chief Medical Officer of Lexeo Therapeutics
“the clinical significance of key assessments used in PKP2-ACM, including the evidence supporting their relevance for evaluating disease burden and treatment response, as well as guideline-based approaches for measurement”
NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that it will host an educational investor event, “Assessing clinically meaningful arrhythmias in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM)” on Wednesday, October 21, 2026 at 1:00 PM ET.
The event will feature a discussion with Narinder Bhalla, M.D., Chief Medical Officer of Lexeo Therapeutics, on the clinical significance of key assessments used in PKP2-ACM, including the evidence supporting their relevance for evaluating disease burden and treatment response, as well as guideline-based approaches for measurement.
Get started
Create a free account to read the full story.